What is eloralintide?

A different receptor entirely

Semaglutide hits one receptor: GLP-1. Tirzepatide hits two: GLP-1 and GIP. Retatrutide hits three, adding glucagon. Every headline obesity drug of the last five years has been a variation on the same incretin theme, stacking more receptors onto the GLP-1 backbone.

Eloralintide breaks that pattern. It does not touch GLP-1, GIP, or glucagon at all. It is a selective agonist of the amylin receptor, a hormone pathway that has nothing to do with the incretin system driving Ozempic, Wegovy, Zepbound, or Mounjaro. Eli Lilly built it, under the internal code LY3841136, as a bet that amylin alone can compete with the drugs that made Lilly's own tirzepatide the best-selling medication in the world.

What amylin actually does

Amylin is a hormone your pancreas already makes, co-secreted with insulin every time you eat. It signals satiety through the area postrema, a region in the brainstem that sits outside the blood-brain barrier and reads circulating hormone levels directly. GLP-1 works through a related but distinct pathway, and part of its effect comes from slowing gastric emptying, which is also the mechanism behind a lot of the nausea and vomiting patients report.

Amylin receptor agonism appears to suppress appetite with less of that gastric slowdown. Eloralintide was also engineered to be selective for the amylin receptor over the closely related calcitonin receptor, a distinction Lilly's own preclinical papers point to as the source of its cleaner tolerability profile compared with older, less selective amylin compounds.

What the Phase 2 trial found

The trial enrolled 263 adults with obesity or overweight and at least one weight-related condition, none of them diabetic. Over 48 weeks, every eloralintide dose arm beat placebo on the primary endpoint. Weight loss ranged from 9.5% at the lowest dose to 20.1% at the highest, against just 0.4% for placebo. The top-dose group averaged roughly 21.3 kg (47 lb) lost. Lead author Liana Billings and coauthors published the full results in The Lancet in November 2025, after Lilly first presented them at ObesityWeek.

Lilly and the trial investigators described the drug as generally well tolerated, with gastrointestinal adverse events lower than what is typically reported for GLP-1 or dual GLP-1/GIP therapy at comparable weight loss. That tolerability claim is the whole reason Lilly is pushing this program forward instead of treating it as a side project.

The muscle-preservation question

A real problem with current obesity drugs: a large share of the weight lost is lean mass, not fat. Estimates run around 45% lean mass loss on semaglutide monotherapy and closer to 25% on tirzepatide. Amylin analogs are being studied specifically because they might avoid that tradeoff.

The evidence for eloralintide on this point is preclinical. In diet-induced obese rats, eloralintide produced greater fat loss and better preservation of lean mass than cagrilintide, Novo Nordisk's amylin analog and the amylin half of CagriSema. That is a rat study, not a human one. No published human trial has yet measured eloralintide's effect on lean mass directly. It is a hypothesis with real preclinical support, not a settled result. For the fuller picture on how much muscle GLP-1 drugs cost and what actually helps protect it, see GLP-1s and muscle loss.

Eloralintide plus tirzepatide

Lilly is not only testing eloralintide alone. It is also running trials combining it with tirzepatide, the active ingredient in Zepbound and Mounjaro, and with a separate incretin candidate called macupatide. At the American Diabetes Association's 2026 meeting in New Orleans, Lilly presented preclinical data from diet-induced obese rats showing that adding eloralintide after two weeks of tirzepatide produced a bigger, more durable drop in food intake than tirzepatide alone, an effect the researchers attributed to the amylin and incretin pathways working on separate, complementary circuits rather than competing for the same one.

Again, that combination data is animal research, not a completed human trial. But it points to how Lilly may actually use this drug commercially: not necessarily as a standalone product competing head-on with Zepbound, but as an add-on that could push tirzepatide's results higher, or as a lower-side-effect option for patients who cannot tolerate the GLP-1 pathway at all.

How it differs from CagriSema

Novo Nordisk got to the amylin idea first with CagriSema, which fixes semaglutide to cagrilintide in a single weekly injection. That is a combination drug by design. Every patient on CagriSema gets both a GLP-1 agonist and an amylin analog, whether they need both mechanisms or not.

Eloralintide is built the opposite way. Lilly is testing it as a monotherapy in non-diabetic adults, as an add-on to tirzepatide, and in adults with type 2 diabetes, keeping the amylin and incretin components separable. If amylin alone proves sufficient for some patients, particularly those who cannot handle GLP-1 side effects, they would not need to take a GLP-1 at all. If the combination proves better, Lilly can pair it with tirzepatide without redesigning the molecule. See what is CagriSema for how Novo Nordisk's combination performed in its own Phase 3 program.

Where it stands now

Eloralintide is early. A single Phase 2 readout and a stack of preclinical rat data are not the same as an approved drug with years of real-world use behind it. But it is the clearest signal yet that the next wave of obesity drugs will not just be more receptors bolted onto the same GLP-1 core. If a drug that never touches GLP-1 can match tirzepatide's weight loss with fewer GI complaints, that changes who these medications can actually work for. For where the rest of the field stands today, see retatrutide vs tirzepatide, or how peptide combinations are being used off-label in peptide stacks.